Reviva Pharmaceuticals Holdings, Inc. filed a preliminary proxy statement on October 29, 2026, calling stockholders to a virtual annual meeting on December 18, 2026, at which they will be asked to vote on five proposals including a potential reverse stock split of up to one-for-one hundred.

Key Highlights

  • Annual meeting date: December 18, 2026 at 11:00 a.m. Pacific Time, held virtually.
  • Reverse split range proposed: One-for-two (1:2) to one-for-one hundred (1:100), at Board discretion, prior to December 31, 2027.
  • Prior reverse split disclosed: A one-for-twenty (1:20) reverse stock split was implemented on March 9, 2026, and all share amounts in the proxy have been retrospectively adjusted.
  • Auditor ratification: Stockholders will vote on retaining Baker Tilly US, LLP as independent registered public accounting firm for the year ending December 31, 2026.
  • Director election: Five director nominees are being put forward to serve until the next annual meeting.
  • Record date: October 30, 2026 is the record date for stockholders entitled to vote.
  • Filing type: This is a preliminary proxy statement; proxy materials were expected to be sent to stockholders on or about November 2026.

Reviva Pharmaceuticals Annual Meeting Proposals and Reverse Split Authorization

Reviva Pharmaceuticals Holdings, Inc., a Cupertino, California-based pharmaceutical company, filed a Schedule 14A preliminary proxy statement with the SEC, disclosing that its 2026 annual stockholder meeting will be held virtually on December 18, 2026. The filing identifies five formal proposals for stockholder action, the most consequential of which is a proposed amendment to the Certificate of Incorporation authorizing a reverse stock split of issued common stock at a ratio ranging from 1:2 to 1:100.

According to the filing, the Board of Directors would retain sole discretion to determine whether to implement the reverse split and, if so, at what specific ratio within the authorized range, at any time prior to December 31, 2027, without requiring further stockholder approval. The proxy also discloses that the company already carried out a one-for-twenty reverse stock split on March 9, 2026, and that all share, warrant, restricted stock, and option figures throughout the proxy statement have been retrospectively adjusted to reflect that earlier split. The filing states that shares, common stock warrants, pre-funded warrants, restricted common stock, and common stock option amounts have all been adjusted accordingly.

In addition to the reverse split proposal, stockholders will consider electing five director nominees, ratifying Baker Tilly US, LLP as the company's independent registered public accounting firm for fiscal year ending December 31, 2026, and approving executive compensation on a non-binding advisory basis. An adjournment proposal is also included to allow additional proxy solicitation if needed to achieve quorum on any of the other proposals. The Board recommends approval of all five proposals, describing each as "advisable and in the best interests" of the company, according to the filing.

What Was Disclosed

Reviva Pharmaceuticals Holdings filed a preliminary proxy statement covering its December 18, 2026 annual meeting, disclosing five stockholder proposals. The central item is a proposed reverse stock split authorization ranging from 1:2 to 1:100, with implementation left to Board discretion before December 31, 2027.